Hologic

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a portfolio of solutions for breast cancer care for radiology, pathology, and surgery. The Diagnostics segment consists of products used to aid in the screening and diagnosis of human diseases. The GYN Surgical segment involves the NovaSure Endometrial Ablation System, the MyoSure Hysteroscopic Tissue Removal System, and the Fluent Fluid Management System. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Hologic exceeds Q1 earnings, eyes growth in women's health

Hologic's Q1 performance surpassed expectations, driven by strong organic growth and strategic initiatives. The company's commitment to women's health, financial strength, and focus on innovation position it well for future growth. Challenges in Breast Health highlight areas for improvement, while opportunities in new markets and products offer avenues for expansion.

Hologic surpasses Q2 expectations, eyes international growth and women's health

Hologic's Q2 performance exceeded expectations, driven by robust organic revenue growth and strong margins across divisions.
While facing challenges like COVID-related revenue declines and seasonal factors, the company's strategic strengths in women's health and international expansion present growth opportunities.
To sustain growth, Hologic must navigate macro uncertainties, balance growth drivers, and capitalize on opportunities in diagnostics and global expansion.
Overall, Hologic's solid financial results, increased revenue guidance, and strategic initiatives position the company for continued success in the healthcare market.

Hologic excels in Q3 earnings, eyes global growth amid challenges

Hologic delivered strong financial results in Q3 2023, driven by robust revenue growth and strategic product offerings across its divisions.
While facing margin challenges and geopolitical uncertainties, the company remains optimistic about sustaining growth and enhancing profitability through operational improvements.
With a focus on innovation, global expansion, and cautious M&A strategies, Hologic is well-positioned to capitalize on opportunities and navigate challenges in the healthcare market.

Hologic surpasses revenue targets, eyes international growth and strategic M&A

Hologic delivered strong financial performance in Q4 2023, exceeding revenue and EPS targets while emphasizing women's health and innovation.
The company's focus on international growth, strategic capital allocation, and product portfolio strength position it well for continued success.
Challenges in regulatory compliance, M&A decisions, and market dynamics require careful navigation for sustained growth.
Opportunities in international expansion, strategic M&A, and product innovation offer avenues for future growth and market leadership.

Hologic surpasses Q1 revenue expectations, eyes international growth opportunities

Hologic delivered strong Q1 2024 results, exceeding revenue guidance and showcasing robust financial performance with organic growth of 5.2% ex-COVID.
The company's focus on innovation, market expansion, and strong customer relationships positions it well for continued growth and success beyond COVID testing.
While facing challenges such as tough comps in Q2 and potential tax rate impacts, Hologic's disciplined growth strategies and commitment to transformative initiatives offer opportunities for future expansion.
With a strong emphasis on AI capabilities, market expansion, and strategic M&A, Hologic is poised for sustained growth and market leadership in the healthcare sector.

Hologic beats Q2 revenue targets, eyes international growth opportunities

Hologic exceeded revenue and EPS expectations in Q2 2024, showcasing growth in key business segments.
While facing challenges in certain revenue streams, the company is focused on international expansion and margin improvement.
Opportunities lie in leveraging international growth, strategic acquisitions, and product utilization trends.
Overall, Hologic's performance reflects resilience post-COVID and strategic focus on innovation and market positioning.

Hologic surpasses Q3 revenue expectations, eyes international growth opportunities

Hologic's Q3 performance reflects resilience and growth across key business segments, supported by strategic investments and operational excellence. With a focus on innovation and international expansion, the company is well-positioned for sustained growth and value creation in the evolving healthcare landscape.

Hologic exceeds Q4 earnings, eyes international growth and new products

Hologic's Q4 2024 earnings call showcased strong performance, strategic strengths, and growth opportunities. Challenges include maintaining margin expansion and balancing international growth. The company's focus on durable revenue base and new product pipeline sets a positive outlook for fiscal 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products, that focuses on women’s health and well-being through early detection and treatment. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment is involved in a portfolio of solutions for breast cancer care primarily in the areas of radiology, breast surgery, pathology and treatment. The Diagnostics segment offers a range of products, which are used primarily to aid in the screening and diagnosis of human diseases. The GYN Surgical segment is involved in hysteroscopic endometrial ablation systems, tissue removal systems, fluid management systems, and laparoscopic tissue ablation systems and tools. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.

Hologic's (HOLX) GYN Surgical Q2 performance was driven by strong results from MyoSure and Fluent Fluid Management.

Hologic's (HOLX) Q2 Earnings Beat Estimates, 2024 View Up

Call Start: 16:30 January 1, 0000 5:24 PM ET Hologic, Inc. (NASDAQ:HOLX ) Q2 2024 Earnings Conference Call May 2, 2024 16:30 ET Company Participants Ryan Simon - Vice President, Investor Relations Steve MacMillan - Chairman, President & Chief Executive Officer Essex Mitchell - Chief Operating Officer Karleen Oberton - Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Jack Meehan - Nephron Research Puneet Souda - Leerink Partners Casey Woodring - JPMorgan Andrew Brackmann - William Blair Andrew Cooper - Raymond James Operator Good afternoon and welcome to the Hologic Second Quarter Fiscal 2024 Earnings Conference Call. My name is Justin and I am your operator for today's call.

Hologic, Inc. (HOLX) Q2 2024 Earnings Call Transcript

While the top- and bottom-line numbers for Hologic (HOLX) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Hologic (HOLX) Reports Q2 Earnings: What Key Metrics Have to Say

Hologic (HOLX) came out with quarterly earnings of $1.03 per share, beating the Zacks Consensus Estimate of $0.97 per share. This compares to earnings of $1.06 per share a year ago.

Hologic (HOLX) Q2 Earnings and Revenues Beat Estimates

MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #earnings--Hologic Announces Financial Results for the Second Quarter of Fiscal 2024.

Hologic Announces Financial Results for Second Quarter of Fiscal 2024

Bruker

Illumina

Teleflex

Zimmer Biomet Hlds

Here is a sneak peek into how the five MedTech stocks, HOLX, ZBH, ILMN, TFX and BRKR, are expected to fare in their quarterly results slated to be released tomorrow.

Will These 5 MedTech Stocks Beat Forecasts This Earnings Season?

MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #acquisition--Hologic to Acquire Endomagnetics Ltd, a Breast Surgical Guidance Company.

Hologic to Acquire Endomagnetics Ltd, a Breast Surgical Guidance Company

Hologic's (HOLX) second-quarter 2024 earnings will likely reflect gains from the GYN surgical business and the growing adoption of Panther instruments.

How You Should Play Hologic (HOLX) Ahead of Q2 Earnings

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Hologic (HOLX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.

Stay Ahead of the Game With Hologic (HOLX) Q2 Earnings: Wall Street's Insights on Key Metrics

Cardinal Health

10X Genomics

Here are three stocks, TXG, CAH and HOLX, which are expected to beat earnings estimates in the ongoing reporting cycle.

3 Medical Products Stocks Set to Beat This Earnings Season

Hologic (HOLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Hologic (HOLX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Hologic (HOLX) reachead $75.36 at the closing of the latest trading day, reflecting a -0.03% change compared to its last close.

Hologic (HOLX) Stock Drops Despite Market Gains: Important Facts to Note

Hologic's (HOLX) second-quarter fiscal 2024 performance is likely to be driven by the GYN Surgical portfolio.

Hologic (HOLX) Q2 Earnings Might Rise on GYN Surgical Growth

Hologic (HOLX) reachead $77.54 at the closing of the latest trading day, reflecting a +0.27% change compared to its last close.

Hologic (HOLX) Increases Despite Market Slip: Here's What You Need to Know

Hologic's (HOLX) Breast Health segment is gaining from a broad portfolio of solutions for breast cancer care, primarily in the burgeoning spaces of radiology, breast surgery, pathology and treatment.

Hologic's (HOLX) New Launches Aid, Macroeconomic Issues Ail

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer and Hologic, Inc. (Nasdaq: HOLX) today announced a first-of-its-kind collaboration to deliver a coordinated solution for contrast-enhanced mammography (CEM). The two companies will showcase the solution at the annual Society of Breast Imaging Symposium from April 11-14, 2024 in Montreal, Canada. Contrast-enhanced mammography is a sensitive and relatively low-cost breast imaging modality that can be used to support breast cancer diagnosis and help to guide.

Bayer and Hologic Collaborating to Deliver Contrast-Enhanced Mammography

MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #earnings--Hologic to Announce Financial Results for the Second Quarter of Fiscal 2024 on Thursday, May 2, 2024.

Hologic to Announce Financial Results for the Second Quarter of Fiscal 2024 on Thursday, May 2, 2024

Hologic (HOLX) closed at $75.65 in the latest trading session, marking a +0.52% move from the prior day.

Hologic (HOLX) Ascends While Market Falls: Some Facts to Note

Hologic (HOLX) concluded the recent trading session at $76.35, signifying a +0.58% move from its prior day's close.

Hologic (HOLX) Rises But Trails Market: What Investors Should Know

In the latest trading session, Hologic (HOLX) closed at $75.64, marking a -0.9% move from the previous day.

Hologic (HOLX) Stock Declines While Market Improves: Some Information for Investors

Hologic's (HOLX) BCI test is the only genomic test that is approved by various national oncology guidelines.

Hologic's (HOLX) BCI Genomic Test Study Outcome Favorable

MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #JNCCN--Newly Published Results Reveal a Significant Proportion of Early-Stage HR+ Breast Cancer Survivors .

Newly Published Results Reveal a Significant Proportion of Early-Stage HR+ Breast Cancer Survivors May Be Over- or Undertreated Without Breast Cancer Index Genomic Testing

The U.S. Food and Drug Administration on Tuesday warned patients and healthcare providers about the potential risk of serious complications arising from the use of Hologic's devices that are implanted in soft tissue.

FDA warns of potential risk of complications with use of Hologic's devices

MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #AI--Hologic to Unveil Groundbreaking AI Research at ECR 2024.

Hologic to Unveil Groundbreaking AI Research at ECR 2024

Hologic aims to elevate women's health globally, with diagnostics making up nearly half of sales. The company experienced a boom in COVID diagnostics sales in 2020 and 2021, creating headwinds thereafter, yet this is set to end in 2024. Amidst a gradual reduction in valuations and improved balance sheet strength, appeal is getting evident here.

News for Hologic Stock (HOLX)